Announcements Trials
Browse Landscape

Phase

Phase NA 2Phase 2/3 2

Status

Unknown 1Terminated 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2Classical hematology 1CNS 1

Conditions

Prostatic Neoplasms 76Urinary Bladder Neoplasms 20Neoplasms 11Carcinoma, Transitional Cell 8Non-Muscle Invasive Bladder Neoplasms 6Lung Neoplasms 6Carcinoma, Renal Cell 6Neoplasm Metastasis 5Breast Neoplasms 4Testicular Neoplasms 3Recurrence 3Prostatic Neoplasms, Castration-Resistant 3Pancreatic Neoplasms 3Ovarian Neoplasms 3Kidney Neoplasms 3Colorectal Neoplasms 3Carcinoma in Situ 3Adenocarcinoma 3Acute Kidney Injury 3Uterine Cervical Neoplasms 2Prostate CA 2Melanoma 2Liver Neoplasms 2Kidney Failure, Chronic 2Hematologic Neoplasms 2Head and Neck Neoplasms 2Gallbladder Neoplasms 2Critical Illness 2Colonic Neoplasms 2Agnosia 2

Interventions

Spironolactone 1Darbepoetin alfa 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2/3 × Critical Illness × Genitourinary × Clear all
NCT02531412 2017-01-04

SPIROCAN

Instituto Nacional de Cancerologia de Mexico

Phase 2/3 Unknown
24 enrolled
Genitourinary

Neoplasms, Critical Illness, Acute Kidney Injury

NCT00381836 2015-12-04

Effect of Darbepoetin Alfa (Aranesp®) on Anemia in Patients With Advanced Hormone Independent Prostate Cancer

University of Aarhus

Phase 2/3 Terminated
140 enrolled
Classical hematologyGenitourinary

Anemia, Fatigue, Neoplasms, Prostatic Neoplasms, Critical Illness

Data powered by HemOnc (CC BY 4.0) Colophon âš¡